Compare Aurora Cannabis Inc (ACB) vs Marvell Technology Inc (MRVL) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Marvell Technology (MRVL) trades at $230.7, down 5.95% amid a sector-wide chip stock selloff. The stock shows strong earnings beats in recent quarters but faces high valuation multiples with a P/E of 85.7 and P/S of 25.0. Technical indicators are neutral, with support near $234 and resistance at $257. Revenue growth is projected to surge to $8.7B in 2026, with net income turning positive to $2.5B, signaling a potential fundamental turnaround.

Outlook: MRVL's AI infrastructure growth and analyst consensus target of $262.6 offer upside, but high valuations and margin pressures pose risks. Investor sentiment is mixed due to semiconductor volatility, though institutional backing remains strong with 82% buy ratings.